Clinical Trial Detail

NCT ID NCT02996110
Title A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma (FRACTION-RCC)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

renal cell carcinoma

Therapies

Nivolumab + Relatlimab

Ipilimumab + Nivolumab

Age Groups: adult senior

No variant requirements are available.